Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab graft purging before autologous stem cell transplant in newly diagnosed multiple myeloma
ISRCTN40735896Phase 3Terminated
- Sponsor
- University of Birmingham
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of daratumumab in multiple myeloma (MM), sponsored by University of Birmingham. Primary endpoint: MRD-negative bone marrow aspirate at day 100 post-ASCT. Started Jan 2021; status: terminated.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ISRCTN40735896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN40735896.